ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Pumpkin Pie Turmeric Breakfast Smoothie - Vegan + Gluten-Free

Vitamin D supplementation extends life in mouse model of Huntington's disease

What’s Fenugreek Good For?

Print Page
Email Article

What Will Happen if We Change the Name? Frequently Asked Questions About CFS and ME

  [ 12 votes ]   [ Discuss This Article ] • June 6, 2013

The CFS/ME community has posed a number of questions concerning the petition to replace the CDC ("Fukuda") criteria with the Canadian Consensus Criteria for ME. The petition calls for dropping the name CFS entirely, replacing it with ME (myalgic encephalomyelitis), the term currently in use in the rest of the world. In this Q&A, Mary Dimmock, one of the founding members of the newly formed organization, National Advocacy Alliance for ME (NAAME), answers frequently asked questions.

You can read the letter to the DHHS HERE.

You can read and sign the petition HERE.


Question: What will happen to the patients who have been diagnosed with CFS? We cannot abandon the patients who have been given a “CFS” diagnosis incorrectly.

Answer: Patients with “CFS” will not be abandoned. It is critical that implementation of this change be carefully managed so that these patients are re-evaluated and given a correct diagnosis. If unexplained conditions remain, it will be necessary to perform the studies needed to understand these conditions and establish more appropriate names and definitions.

Question: How will this affect disability or insurance? We cannot afford to lose either one. 

Answer: It will be important to have a carefully thought out implementation plan that manages this change to ensure that patients do not lose disability or insurance benefits simply as a result of changing the diagnosis.

Question: The vast majority of the 6000 articles in the literature use the name “CFS,” not “ME. If we stop using the name “CFS,” will we lose all that literature?

Answer: Researchers and professionals routinely learn about the history of names and definitions associated with any disease. They also need to understand what criteria were used in the past for any study under review. 

This is especially critical with the “CFS” literature, because while it contains good research studying the essential features of ME, it also contains studies that used patients who met other conditions (i.e. depression and deconditioning) falling under the Oxford and Fukuda (CDC) case definitions. As a result, much of the “CFS” data does not represent one illness or even one illness with subsets, but rather a variety of “fatiguing conditions,” which have been thrown into the CFS diagnosis-of-exclusion wastebasket.

Continuing to use the “CFS” label will only exacerbate a very confusing situation, doing a disservice to ME patients and to all patients who deserve to be properly diagnosed and treated.

Question: We have more important issues to deal with such as funding, and attracting new doctors and researchers. Isn’t this just a side issue?

Answer: It is critical that we have more funding, but if we don’t fix the definition first, we will continue to study the wrong disease and have progress impeded by poor cohorts. The resulting confusion will make it difficult to attract young researchers and doctors who will not see a career opportunity in “CFS.”

Question: Research centers for CFS have recently been established. If we stop using the name “CFS” won’t that confuse the donors?

Answer: It is true that a number of research institutes have recently been opened and some of them use the term “”CFS” or even “CF.” But the donors to these institutes have a personal connection to the disease. They will continue to fund the centers no matter what the illness is called. However, attracting additional funders will be hindered by the confusion generated by the definition of the disease. The sooner we can resolve this problem, the better off we’ll be.

Question: CFS biobanks have been established using the Fukuda criteria. Will we lose those samples if the definition is changed? 

Answer: The biobanks using the Fukuda definition could contain a mix of patients with ME and those who don’t. Using these mixed samples will continue to confound research. It is important that we have a well-characterized set of samples in the biobank and know which samples are from ME patients.

Question: ME may not be the right name. Shouldn’t we wait for science to figure out what the right name is?

Answer: It is possible that with further study we will eventually determine a better name. But because ME was adopted by the World Health Organization in 1969, it is the best placeholder until that time and avoids the serious problems caused by the use of the term “CFS”.

Question: Wouldn’t the best course be to tighten up the “CFS” definition, not get rid of it? Then we can keep the literature base, the biobanks, and so on.

Answer: There are two problems with this approach. First is the long history of the term “CFS,” which is non-specific and now widely associated with diverse conditions, especially psychiatric illnesses. This has tainted the term and made it clinically meaningless. Second, the term “CFS” is used for those studying patients who meet the Oxford criteria (which is essentially fatigue). As long as we keep the term “CFS” the Oxford criteria will remain in effect.

Question: Dr. Leonard Jason recently published a paper that reports that the ME-ICC and the Canadian Consensus Criteria include more psychiatric co-morbidities than the Fukuda definition, and recommended that more study be done. Does that mean we should wait to recommend any criteria until then?

Answer: Dr. Jason acknowledged that his study was limited due to the use of a questionnaire designed for the Fukuda definition. Additionally, the study was unable to assess one of the key ME-ICC symptoms because the data were not available. Finally, the study did not look at homebound or bedbound patients. 

What is also significant in Dr. Jason’s study is that ME-ICC identified a much tighter group of patients (39 compared to 113 for Fukuda) with more functional impairments and physical, mental and cognitive problems than those meeting the Fukuda criteria. 

Clearly, additional study is needed to operationalize the definition and to improve how it characterizes the disease, especially subtypes. But continuing to use the 19-year-old Fukuda definition - which is also not operationalized and does not describe subtypes - is not going to advance scientific knowledge and will only continue to hurt patients. 

The Canadian Consensus Criteria (CCC) has been used clinically and in research for over ten years. There is no doubt that it better represents the disease. Using the CCC now will allow us to begin to make progress in research and to address the widespread dismissive attitude held by the medical community.

Question: We still don’t know for sure that post-exertional malaise (PEM) is real and we don’t have agreement on how to measure it. How can PEM be used by researchers as a primary symptom?

Answer: The work of Dr. Christopher Snell as well as the work of the Lights have not only demonstrated the reality of PEM but have provided the objective test to demonstrate it using the two- day cardiopulmonary exercise test (CPET). This test is the gold standard for functional capacity evaluations and is approved by a number of major American medical societies and organizations.

Question: Why were the Canadian Consensus Criteria and not the ME-International Consensus Criteria used as the initial baseline?

Answer: The Canadian Consensus Criteria has been used clinically and in a number of studies, providing the experiential foundation for its use. It is expected that as additional data is obtained, this definition will evolve. This must be done in partnership with the experts who developed the ME-International Consensus Criteria and the Canadian Consensus Criteria.

Question: Isn’t the Canadian Consensus Criteria is too complicated for doctors to use?

Answer: At the May, 2013 CFS Advisory Committee meeting (CFSAC), Dr. Unger raised a concern that the Canadian Consensus Criteria is too complicated for doctors. But we must not lose sight of the fact that this is a complicated disease and simple criteria, especially those like Fukuda and Oxford, that fail to require the hallmark symptoms of the disease are misleading doctors and hurting patients every day. Any doctor capable of treating the complexity of this disease will be able to understand the Canadian Consensus Criteria.

Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Clinically Studied Joint Relief Product for FM & ME/CFS Clinically Studied Joint Relief Product for FM & ME/CFS
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Coconut Oil - Healthy Gifts from the 'Tree of Life' Coconut Oil - Healthy Gifts from the 'Tree of Life'
Probiotic Mint Promotes Healthy Gums & Teeth, Freshens Breath and Whitens Teeth Probiotic Mint Promotes Healthy Gums & Teeth, Freshens Breath and Whitens Teeth
Bone Broth Benefits for Digestion, Arthritis and Cellulite Bone Broth Benefits for Digestion, Arthritis and Cellulite

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map